Overview
- Earnings per share reached $1.26 for the quarter, topping the $0.63 consensus, as sales rose to $104.27 million versus $11.5 million a year ago and ahead of the $86.02 million estimate.
- DefenCath drove the quarter with $88.8 million of net revenue, pushing reported net revenue to $104.3 million and pro forma net revenue to $130.8 million on stronger-than-expected outpatient dialysis uptake.
- Management raised full-year 2025 pro forma net revenue guidance to $390–$410 million and set fourth-quarter net revenue guidance at $115–$135 million.
- The company increased its 2025 fully synergized pro forma adjusted EBITDA outlook to $220–$240 million as Melinta integration progresses ahead of plan with roughly $30 million of run-rate synergies expected before the end of 2025.
- CorMedix reported net income of $108.6 million, adjusted EBITDA of $71.9 million, and cash and short-term investments of $55.7 million, while the stock rose about 12% following the release.